-
NMPA Announcement on Issues about Implementing the Rules for Registration and Notification Dossiers of Cosmetics
2021-03-05
In order to implement the Regulations for the Supervision and Administration of Cosmetics and the Provisions for Registration and Notification of Cosmetics and further standardize the administration on registration and notification of cosmetics, the issues about implementing the Rules for the Registration and Notification Dossiers of Cosmetics is hereby announced as follows.
-
NMPA Announcement on Issuing the Rules for Registration and Notification Dossiers of Cosmetics
2021-03-04
The NMPA has developed the Rules for Registration and Notification Dossiers of Cosmetics, which is hereby issued and shall take effect as of May 1, 2021.
-
NMPA Announcement on Issuing the Rules for Registration and Notification Dossiers of New Cosmetic Ingredients
2021-03-04
The NMPA has developed the Rules for Registration and Notification Dossiers of New Cosmetic Ingredients, which is hereby issued and shall take effect as of May 1, 2021.
-
NMPA Announcement on Revising the Package Insert of Misoprostol Tablets for Obstetrical and Gynecological Application
2021-02-26
To further protect public medication safety, the NMPA decided to revise the package insert of Misoprostol Tablets for obstetrical and gynecological application. Relevant issues are hereby announced as follows.
-
NMPA Notice on Issuing the Requirements for Change Items of Marketed Traditional Chinese Medicines and Application Dossiers
2021-02-24
The NMPA has organized to formulate the Requirements for Change Items of Marketed Traditional Chinese Medicines and Application Dossiers, which has been issued and implemented on February 23.
-
NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs (Thirty-eighth Batch)
2021-02-23
On February 20, the Catalogue of Reference Preparations of Generic Drugs (Thirty-eighth Batch) was issued, upon review and determination by the NMPA Experts Committee of Quality and Efficacy Consistency Evaluation of Generic Drugs.